Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer
NCT05068024 is registered in ClinicalTrials.gov with Forward Pharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer
- Lead sponsor
- Forward Pharmaceuticals Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- August 23, 2021
- Completion date
- December 30, 2025
- Enrollment
- 30 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.